BioCentury
ARTICLE | Finance

Cross-border cachet

Vivace’s plans to leverage China-U.S. model to retain more pipeline value

July 5, 2017 8:55 PM UTC

Vivace Therapeutics Inc.’s investors are hoping to leverage the management team’s experience running a U.S.-China cancer company, but this time the goal is to retain more value by advancing the programs into the clinic.

Vivace emerged from stealth mode on June 28 with a $25 million series B round led by Cenova Capital. Fellow new investor Sequoia Capital China and existing investors Canaan Partners, WuXi Healthcare Ventures and Mission Bay Capital also participated. Canaan and WuXi co-led Vivace’s $15 million series A round in 2015...

BCIQ Company Profiles

Vivace Therapeutics Inc.